Neogen reported earnings per share of $0.08 and revenue of $222.8 million, both exceeding analyst expectations. The company also announced a strategic partnership with Hinalea Imaging Corp. to develop digital food safety tools. However, Neogen's stock dropped over 7% following an FDA warning about a recalled equine product, HYCOAT, raising concerns and triggering a securities-law investigation. This mix of strong financial results and product quality issues creates uncertainty for investors.
Neogen's earnings report and FDA product warning provide context for readers. For those tracking Consumer Staples-sector US stocks on Pluang, as of Oct 07, 2026 03:16 WIB, 32 of 51 stocks rose while 18 fell. Notable price changes include MDLZ at USD 57.85 with a 1-day change of -1.62%, CL at USD 85.61 up 1.60%, and SAM at USD 170.30 up 1.56%. The most notable figure is MDLZ's 0% Sell / 100% Buy Pluang order activity.
PepsiCo is set to report its Q3 2026 earnings with expectations of $2.29 EPS and $25 billion revenue. The company faces challenges in North America, where organic revenue declined due to pricing pressures and changing consumer preferences. To adapt, ...
Stryker experienced an 8.8% stock drop on September 8, 2026, wiping out over $10 billion in market value due to ongoing manufacturing problems that were thought resolved. Truist Financial lowered its price target from $340 to $310, reflecting concern...
Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...
Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...
Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...
